ERBB2 and breast cancer: More recently, in 2019, the FDA expanded the approved use of ado-trastuzumab emtansine for the treatment of early-stage high-risk HER2-positive breast cancer patients with residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment [96].